文献速递贫血与红细胞疾病MDS 与骨髓增殖性肿瘤

预测性再生障碍性贫血评分系统(PASS)的建立与验证:成人获得性再生障碍性贫血诊断的简化工具

Development and validation of the predictive aplastic score system (PASS): a simplified tool to diagnose acquired aplastic anemia in adults.
PubMed 文献 · Leukemia · 2026-04-27

研究基于212例成人(162例AA,50例IBMFS)建立PASS评分,采用LASSO逻辑回归筛选7个临床变量,训练队列AUC为0.990(95%CI 0.982-0.999),评分≥30对AA的PPV为100%。在4个外部队列716例中验证AUC为0.977(95%CI 0.968-0.987),评分≥30可快速诊断80%的AA病例。

要点

  • PASS评分≥30对成人AA的阳性预测值为100%,可快速诊断80%的AA病例。
  • PASS评分<0的患者中86.8%为IBMFS,有助于排除AA。
  • PASS使用7个易获取临床变量,并已开发开放获取网页计算器。

核心结论

  • PASS是一种实用且准确的临床工具,可快速区分大多数成人AA与IBMFS。

研究设计与样本

  • 训练队列纳入212例成人,其中AA 162例、IBMFS 50例。
  • 采用LASSO逻辑回归筛选7个临床变量构建模型。
  • 在4个外部队列共716例患者中验证PASS。

主要发现

  • 训练队列AUC为0.990(95%CI 0.982-0.999)。
  • 评分≥30对AA的PPV为100%。
  • 评分<0的患者中86.8%为IBMFS。
  • 外部验证队列AUC为0.977(95%CI 0.968-0.987)。
  • 阈值分析确认评分≥30对AA的PPV为100%,可快速诊断80%的AA病例。

关键数值与推荐

  • PASS模型纳入7个变量:严重程度、急性程度、年龄、IBMFS警示信号、AA相关疾病、AA相关体细胞改变和端粒长度。
  • 评分≥30对AA的PPV为100%。
  • 评分<0的患者中86.8%为IBMFS。

临床怎么用

  • PASS可利用易获取的临床数据辅助区分成人AA与IBMFS。
  • 评分≥30可快速诊断80%的AA病例,有助于及时启动治疗。
  • 已开发开放获取网页计算器(https://pennmedicine.shinyapps.io/passcalc/)促进临床使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acquired aplastic anemia (AA) can present similarly to inherited bone marrow failure syndromes (IBMFS) but treatment differs. AA diagnosis relies on excluding IBMFS; however, genetic testing is not always available, may delay care or be inconclusive. We developed the Predictive Aplastic Score System (PASS), a clinical tool using readily available data to distinguish AA from IBMFS in adults. The training cohort included 212 adults (162 AA, 50 IBMFS). Compared to IBMFS, AA patients were older and more likely to have acute-onset, severe cytopenias. Using logistic regression with LASSO, we selected seven clinical variables for model inclusion: severity, acuity, age, IBMFS red flags, AA-associated conditions, AA-associated somatic changes, and telomere lengths. The model achieved AUC of 0.990 (95% CI: 0.982-0.999), with 100% positive predictive value (PPV) for AA for scores ≥30. 86.8% of patients with scores <0 had IBMFS. We validated PASS in 716 patients from four external cohorts with AUC of 0.977 (95% CI: 0.968-0.987). Threshold analysis confirmed 100% PPV for scores ≥30, rapidly diagnosing 80% of AA cases. PASS is a practical and accurate clinical tool that can rapidly distinguish AA from IBMFS for most adult patients. To promote clinical adoption, we developed an open-access web calculator ( https://pennmedicine.shinyapps.io/passcalc/ ).

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Aleixo G, Cheon H, Zheng J, et al. Development and validation of the predictive aplastic score system (PASS): a simplified tool to diagnose acquired aplastic anemia in adults. Leukemia. 2026. PMID: 42045556. doi:10.1038/s41375-026-02924-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。